Climb Bio, Inc.
CLYM - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$585.28M
Close$
$0.52
94.6% downside
Current Fair Value
94.6% downsideOvervalued by 94.6% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $585.28 Million |
|---|---|
| Enterprise Value | $542.48 Million |
| Earnings per Share | $-0.88 |
| Beta | 0.08 |
| Outstanding Shares | 76,154,071 |
Return
| Return on Equity | -24.06% |
|---|---|
| Return on Assets | -23.40% |
| Return on Invested Capital | -27.00% |
Valuation & Multiples
| P/E Ratio | -12.28 |
|---|---|
| PEG | -22.02 |
| Price to Sales | - |
| Price to Book Ratio | 3.19 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -8.36 |
| Enterprise Value to Net Income | -10 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0.01 |
Revenue Sources
No data
Last Earnings Call
Report Date
August 6, 2026
EPS Estimate
$-0.21
Consensus analyst estimateRevenue Estimate
-
Consensus analyst estimateNext Earnings Call
Expected Date
November 11, 2026
EPS Estimate
$-0.20
Consensus analyst estimateRevenue Estimate
-
Consensus analyst estimateInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
About Eliem Therapeutics Inc
2,021 employees
CEO: Aoife Brennan BCh MMSc
Climb Bio, Inc. is a biopharmaceutical firm dedicated to crafting therapeutic solutions for inflammatory diseases driven by autoimmune responses. Its primary investigational asset is budoprutug, an anti-CD19 monoclonal antibody. This tre...